Answers are grounded in this paper and cite their sources.
Human papillomavirus (HPV) causes 660,000 cases and 350,000 deaths globally despite effective vaccination, screening, and treatment options; few are feasible to implement in resource-limited settings where the burden of cervical cancer is high. A single-dose, multivalent HPV vaccination of adolescent females could prevent the majority of cancers, making it the undisputed priority. However, vaccination programs leave a decades-long time lag between prophylaxis of HPV infection and cancer prevention in later adulthood. Screening for and treatment of precancer in mid-adulthood could save additional millions of lives. There are pertinent scientific facts concerning HPV natural history and cervical carcinogenesis so firmly established that they are beyond reasonable dispute. With the realization that scientific certainty demands extraordinary evidence that will always be further refined, a group of cervical cancer prevention specialists with experience in resource-limited settings met intending to posit such a set of fundamental scientific principles.
No takes yet. Share an insight, caveat, or question.
SCHIFFMAN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: